Subcutaneous T-cell lymphoma.

J Am Acad Dermatol

Department of Dermatology, University of Erlangen-Nümberg, Germany.

Published: February 1997

We describe a patient with severe fatal histiocytic phagocytic panniculitis caused by a pleomorphic T-cell lymphoma. Analysis by polymerase chain reaction revealed clonality for both the T-cell receptor gamma-chain gene and the immunoglobulin heavy-chain gene. We also review 44 reported cases of primary or secondary lymphoma affecting the subcutaneous fat.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0190-9622(97)80400-8DOI Listing

Publication Analysis

Top Keywords

t-cell lymphoma
8
subcutaneous t-cell
4
lymphoma describe
4
describe patient
4
patient severe
4
severe fatal
4
fatal histiocytic
4
histiocytic phagocytic
4
phagocytic panniculitis
4
panniculitis caused
4

Similar Publications

Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity.

Clin Cosmet Investig Dermatol

January 2025

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations.

View Article and Find Full Text PDF

Introduction: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have an unmet medical need. The objective of this trial was to assess the efficacy and toxicities of a novel triple immunotherapy regimen-pembrolizumab, low-dose cyclophosphamide, and maveropepimut-S (MVP-S). This regimen was designed to activate tumor-specific T cells by targeting the tumor-associated antigen survivin with MVP-S and reducing two important T cell inhibitory pathways: T cell exhaustion and regulatory T cells with pembrolizumab and metronomic cyclophosphamide, respectively.

View Article and Find Full Text PDF

The potential synergistic effect of combining doxorubicin with vorinostat in urothelial carcinoma therapy.

Heliyon

January 2025

Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi City, Taiwan.

Bladder cancer ranks as the 9th most common type of cancer worldwide. Approximately 70 % of bladder cancers are diagnosed as non-muscle invasive, and they are treated with transurethral resection followed by intravesical therapy. Doxorubicin is one of the effective cytotoxic drugs used in intravesical and systemic therapy, but its cardiotoxicity and nephrotoxicity limit therapeutic dosages.

View Article and Find Full Text PDF

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel immunotherapy for the treatment of refractory malignancies. While various complications have been described previously, sclerosing cholangitis has not been reported. We report the first description of sclerosing cholangitis secondary to Tecartus CAR-T therapy in a 67-year-old man with refractory stage IV mantle cell lymphoma.

View Article and Find Full Text PDF

Background: The outcomes of pediatric patients with acute lymphoblastic leukemia (ALL) remain far less than favorable. While apigenin is an anti-cancer agent, studies on the mechanism by which it regulates ALL cell cycle progression are inadequate. Ferroptosis and AMP-activated protein kinase (AMPK) signaling are important processes for ALL patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!